Population-estimated clearance of Trastuzumab Emtansine (T-DM1)
Estimates the clearance of Trastuzumab Emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. The model was based on pooled data from a phase I trial and 2 phase II trials.
Research authors: Gupta M, Lorusso PM, Wang B, Yi JH, Burris HA 3rd, Beeram M, Modi S, Chu YW, Agresta S, Klencke B, Joshi A, Girish S.
  • Clinical pharmacology
  • {{ modelType }}
  • Details
  • Validate model
  • Save input
  • Load input

Population-estimated clearance of trastuzumab emtansine L/d

{{ resultSubheader }}
{{ chart.title }}
Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

Conditional information

This population pharmacokinetic (PK) model by Gupta et al1 estimates the clearance of trastuzumab emtansine (T-DM1) based on a large and representative patient population that has received prior trastuzumab-based therapy. This model should support exposure comparisons of different dosage regimens, as well as PK and pharmacodynamic studies of T-DM1. Patients with larger body weight, lower albumin, higher tumor burden, and higher AST had faster clearance. Creatinine clearance was found to have no influence on T-DM1 clearance.1

Limitations of the model:
The applicability of the derived population PK model might be limited to the T-DM1 concentration ranges where PK is linear. The PK of T-DM1 in patients on earlier lines of therapy has yet to be fully elucidated from ongoing trials.1

Model performance: 
In a study by Gupta et al (2012), there was good agreement between observed and predicted concentrations. The goodness-of-fit plots for the model demonstrated good agreement between the observed and predicted concentration values.
Body weight, albumin, tumor burden, and AST were statistically significant covariates that influenced the pharmacokinetics of T-DM1, explaining 37%
of interindividual variance in the clearance of T-DM1. Interindividual variability of clearance was reduced from 26.4% to 21% (decrease of 36.7%) after adding the models' covariates.1 


References: 
1Gupta M, Lorusso PM, Wang B et al. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics oftrastuzumab emtansine, a HER2- targeted antibody-drug conjugate, in patients with HER2-positive metastaticbreast cancer. Journal of Clinical Pharmacology, 2012;52:691-703.
 

Note
Notes are only visible in the result download and will not be saved by Evidencio
{{ file.classification }}

Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

Underlying models Part of
Comments
Comment
Please enter a comment
Comments are visible to anyone

Model feedback

No feedback yet 1 Comment {{ model.comments.length }} Comments
On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
logo

Please sign in to enable Evidencio print features

In order to use the Evidencio print features, you need to be logged in.
If you don't have an Evidencio Community Account you can create your free personal account at:

https://www.evidencio.com/registration

Printed results - Examples {{ new Date().toLocaleString() }}


Evidencio Community Account Benefits


With an Evidencio Community account you can:

  • Create and publish your own prediction models.
  • Share your prediction models with your colleagues, research group, organization or the world.
  • Review and provide feedback on models that have been shared with you.
  • Validate your models and validate models from other users.
  • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction models and their data.
  • Use patient specific protocols and guidelines based on sequential models and decision trees.
  • Stay up-to-date with new models in your field as they are published.
  • Create your own lists of favorite models and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.


Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.
Evidencio v3.0 © 2015 - 2021 Evidencio . All Rights Reserved